Carbone Cancer Center part of breast cancer vaccine clinical trial

The Carbone Cancer Center at UW–Madison is one of three institutions in the U.S. participating in a clinical trial for a vaccine designed to prevent the recurrence of triple-negative breast cancer, according to a report from WKOW ABC-27.

Triple-negative breast cancer accounts for 10–15% of all breast cancer diagnoses, and the American Cancer Society says these cancer cells are difficult for many current cancer treatments to treat.

All patients in the trial must have had stage 1–3 triple-negative breast cancer in the last three years and have been curatively treated. The trial will expand to more than 30 participants across UW Carbone and the other two sites at Johns Hopkins University and the University of Washington School of Medicine. The patients will be monitored monthly to see the effects of the vaccine.